Physician profile
Christine Mccrary
NPI 1144234295
$1,234.23
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $75.44 · 2022: $214 · 2023: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $149.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $353.66 | 2019-2023 | |
| Janssen Biotech, INC. | $199.83 | 2019-2023 | Tremfya |
| Abbvie INC. | $157.59 | 2019-2023 | |
| Amgen INC. | $126.55 | 2019-2023 | Enbrel, Otezla, Tavneos |
| Aurinia Pharma U.S., INC. | $94.88 | 2022-2023 | Lupkynis |
| Genentech USA, INC. | $74.85 | 2019 | |
| Hikma Pharmaceuticals USA | $49.67 | 2019 | |
| Glaxosmithkline, LLC. | $35.60 | 2019 | |
| Sobi, INC | $34.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.06 | 2019 | |
| Lilly USA, LLC | $24.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.57 | 2020 | |
| Mallinckrodt Enterprises LLC | $17.87 | 2019 | |
| Merck Sharp & Dohme LLC | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Mccrary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.